Using uMRD Can Guide Venetoclax Duration in CLL
August 14, 2025
MRD guided venetoclax based therapy can lead to durable remissions in both the frontline and relapsed/refractory (R/R) setting in CLL
MRD guided venetoclax based therapy can lead to durable remissions in both the frontline and relapsed/refractory (R/R) setting in CLL
MRD-guided ibrutinib plus venetoclax is a very effective combination therapy for treating CLL, and it can provide durable responses.
Patients with CLL who were able to rapidly clear measurable residual disease (MRD) needed less treatment and experienced longer remissions.
Data suggests that patients with CLL who are on venetoclax plus obinutuzumab and reach undetectable MRD may be able to discontinue therapy early.
Testing for measurable residual disease (MRD) through next-generation sequencing (NGS) with clonoSEQ revealed zero to one cell per million in the blood.
Measurable residual disease (MRD) testing measures the amount of cancer cells that are present in blood or bone marrow at the time the sample was collected.
It’s been a month since my last post on progress in my trial of epcoritamab, a bispecific T cell engager (BiTE) for my chronic lymphocytic leukemia.
MRD guided acalabrutinib, venetoclax and obinutuzumab led to an 88% progression free survival rate in relapsed / refractory chronic lymphocytic leukemia.
Measurable residual disease (MRD)-guided treatment of CLL with ibrutinib plus venetoclax significantly increased time in remission.